We were notified by one of the readers that the section Therapeutic siRNA Bioconjugates for Clinical Application lacks one critical reference. After careful consideration, we feel the reference should be included, and so wish to add this context and list the citation: In the penultimate paragraph of this section, we wish to change the sentence that reads, “Recently, Avidity Biosciences announced that their antibody–oligonucleotide conjugates enabled significant silencing of myostatin mRNA in unspecified muscle tissues, which might provide a new way for delivery of ARCs to nonliver tissues^62,63” to read as follows: “Following the work of Sugo et al. on ARCs targeting transferrin receptors via intramuscular injection,(1) Avidity Biosciences reported that their antibody-siRNA conjugate enabled significant silencing of myostatin mRNA in muscle, which further demonstrates the promise of this novel mode of therapeutics.^62,63” This article references 1 other publications.

中文翻译：

---

除了“治疗性共轭趋势：从临床到临床”。

一位读者通知我们，“临床用治疗性siRNA生物缀合物”部分缺少关键的参考文献。经过仔细考虑，我们认为应该包括参考文献，因此希望添加此上下文并列出引用：在本节的倒数第二段中，我们希望更改以下句子：“最近，Avidity Biosciences宣布其抗体–寡核苷酸偶联物可在未指定的肌肉组织中显着抑制肌生成抑制素mRNA，这可能为将ARC传递至非传递组织提供了新途径^62,63”的内容如下：“在Sugo等人的工作之后，（1）Avidity Biosciences报道，它们的抗体-siRNA共轭物可显着沉默肌肉中肌生长抑制素mRNA的沉默，这进一步证明了这种新型治疗方法的前景。^62,63 ”本文引用了其他1个出版物。